Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy

NCT00412334 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00412334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00412334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
September 30, 2010
Enrollment
104 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic